Glasdegib Brand names: Daurismo

What is glasdegib used for?

From the label: indications and usage

DAURISMO is indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy. DAURISMO is a hedgehog pathway inhibitor indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.

Conditions named in the indications of glasdegib's FDA labels, with every medicine labeled for each:

• Leukemia, lymphoma and myeloma

FDA pharmacologic class: Hedgehog Pathway Inhibitor.

What does the patient leaflet for glasdegib say first?

The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.

From the patient leaflet: What is the most important information I should know about DAURISMO?

DAURISMO can cause your baby to die before it is born (be stillborn) or cause your baby to have severe birth defects. For females who can become pregnant: • You should talk to your healthcare provider about the risks of DAURISMO to your unborn child. • Your healthcare provider will do a pregnancy test within 7 days before you start taking DAURISMO. • You should not use DAURISMO during pregnancy. • You should use effective birth control during treatment and for at least 30 days after your last dose of DAURISMO. Talk with your healthcare provider about what birth control method is right for you during this time. • Talk to your healthcare provider right away if you have unprotected sex or if you think that your birth control has failed. • Tell your healthcare provider right away if you become pregnant or think that you may be pregnant. For males: • It is not known if DAURISMO is present in semen. Do not donate semen during treatment with DAURISMO and for at least 30 days after your last dose. • You should always use effective birth control, including a condom, even if you have had a vasectomy, during sex with female partners who are pregnant or who are able to become pregnant, during treatment with DAURISMO and for at least 30 days after your last dose to protect your female partner from being exposed to DAURISMO. • Tell your healthcare provider right away if your partner becomes pregnant or thinks she is pregnant while you are taking DAURISMO. Exposure to DAURISMO during pregnancy: If you think that you or your female partner may have been exposed to DAURISMO during pregnancy, talk to your healthcare provider right away. If you become pregnant during treatment with DAURISMO, you or your healthcare provider should report your pregnancy to Pfizer at 1-800-438-1985.

From the patient leaflet: What should I avoid while taking DAURISMO?

Do not donate blood or blood products during treatment with DAURISMO and for at least 30 days after the last dose. • Do not donate semen during treatment with DAURISMO and for at least 30 days after the last dose.

From the patient leaflet: How should I store DAURISMO?

Store DAURISMO at room temperature between 68°F to 77°F (20°C to 25°C). Keep DAURISMO and all medicines out of the reach of children.

Is there a generic for glasdegib (Daurismo)?

No generic glasdegib is approved (Drugs@FDA, October 8, 2026).

The Orange Book lists 5 patents for Daurismo tablets: the compound patent runs to April 13, 2036. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.

What does the glasdegib label say about other medicines?

The glasdegib label names 1 other medicine in its interaction, contraindication or warning sections. The labels of 2 other medicines name glasdegib. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.

Other labels that name glasdegib

• Itraconazole
• Voriconazole

Check glasdegib against other medicines

What do FAERS reports show for glasdegib?

The FDA Adverse Event Reporting System holds 468 reports that list glasdegib among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 190 are coded as a death and 224 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.

The most reported reactions

• Death (an outcome recorded in the report)110
• Febrile Neutropenia (named in the label)69
• Pneumonia (named in the label)48
• Off Label Use (a use or a product term, not a reaction)34
• Neoplasm Progression28
• Neutropenia (named in the label)22
• Sepsis (named in the label)15
• Toxicity To Various Agents13

Side effects: the label's list and every FAERS reaction

What else is labeled for the same conditions as glasdegib?

37 other medicines are given the same way (oral) and in the same FDA class as glasdegib or labeled mainly for the same use (leukemia, lymphoma and myeloma), the same class first. Leukemia, lymphoma and myeloma lists all 98 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.

What next?

Other hedgehog pathway inhibitors

the pharmacologic class, with prices and generics

Glasdegib side effects

the label's list beside FAERS reports

Check an interaction

what two or more labels say about each other